Andreas Papapetropoulos

Professor Andreas Papapetropoulos is a faculty member at the University of Athens, affiliated with the Faculty of Pharmacy and the Department of Pharmaceutical Chemistry. His academic career spans multiple roles, including Visiting Professor at institutions like UMDNJ, UTMB, and McGill University, and editorial board memberships for journals such as the British Journal of Pharmacology and Arteriosclerosis, Thrombosis and Vascular Biology.

He earned a BSc in Pharmacy from the University of Patras (1985–1989) and a PhD in Pharmacology from the Medical College of Georgia (1990–1994), followed by postdoctoral training at Yale University. His research focuses on Gasotransmitters (NO and H2S), Molecular Pharmacology, Cardiovascular Pharmacology, and Cell Signaling, with a particular emphasis on Preclinical Drug Screening and Oxidative Stress.

• Preclinical drug screening
• Molecular pharmacology
• Cardiovascular pharmacology
• Cell signaling and vascular biology
• Gasotransmitter (NO/H2S) pharmacology
• Mitochondrial bioenergetics
• Vascular redox biology

His recent publications highlight advancements in Hydrogen Sulfide (H2S) signaling, including studies on mitochondrial enzyme localization, metabolic syndrome, and cardioprotective H2S donor combinations. He has also contributed to regulatory pharmacology through reviews of novel drug approvals by the EMA, FDA, and MHRA.

Scientific distinctions include being a Fellow of the American Heart Association and the British Pharmacological Society, recognition in the Most Influential Greek Scientist list, and inclusion in the Top 1% of Scientists by Citations. Additional roles include Chair Secretary General of the European Network of Gasotransmitters and National Delegate to the European Medicines Agency Pediatric Committee.